A clinical Response in Metastatic Castration-resistant Prostate Cancer (mCRPC) Cases Treated with Supra-physiological Doses of Testosterone: Bipolar Androgen Therapy
Senji Hoshi1, Vladimir Bilim2, Kiyotsugu Hoshi1, Takuya Nakagawa3, Sadanobu Sato3, Rie Sakagami3, Masato Konno3, Takashi Kudo3, Kenji Numahata3, Isoji Sasagawa1
  1. Department of Urology Yamagata Tokushukai Hospital, Yamagata Japan.
  2. Department of Urology Kameda Daiichi Hospital, Niigata Japan.
  3. Department of Urology Yamagata Prefectural Central Hospital, Yamagata Japan.
Senji Hoshi senjihoshi47@yahoo.co.jp
Vladimir Bilim vbilim@zoho.com
Kiyotsugu Hoshi kiyotsugu49@yahoo.co.jp
Takuya Nakagawa ntakuya19930527@gmail.com
Sadanobu Sato nobusada0517@gmail.com
Rie Sakagami rier060209@gmail.com
Masato Konno m1zinedine19@gmail.com
Takashi Kudo takashi0218kudo@yahoo.co.jp
Kenji Numahata numapyon.tom@gmail.com
Isoji Sasagawa isoji.sasagawa@tokushukai.jp
Keywords: prostate cancer, metastatic castration-resistant prostate cancer, testosterone injection, bipolar androgen therapy
Abbreviations:
T – testosterone
PCa – prostate cancer CRPC – castration-resistant prostate cancer mCRPC – metastatic castration-resistant prostate cancer
GS – Gleason score
iPSA – initial PSA
RRP – radical retropubic prostatectomy
ADT – androgen deprivation therapy MAB – maximal androgen blockade ARAT – androgen receptor-axis-targeted therapies EBRT – external beam radiation therapy
QOL – quality of life
BMA – bone modifying agents
BAT – bipolar androgen therapy
AR – androgen receptor